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Purpose: Thoracic endovascular aortic repair is increasingly becoming the standard treatment of many thoracic aortic
pathologies. New reliable and accurate stent grafts are emerging to widen the endovascular treatment options. We report
the results of RELAY (BoltonMedical, Barcelona, Spain) in the large RELAYEndovascular Registry for Thoracic Disease
(RESTORE) European registry.
Methods:RESTORE is amulticenter, prospective European registry involving 22 centers in seven European countries. The
RELAY device is composed of a stent graft (self-expanding nitinol stents and a polyester vascular graft) and a delivery
device specifically designed for the thoracic aorta. Included were acute and elective patients presenting with a variety of
pathologies (aneurysms, dissections, ulcerations, intramural hematomas, pseudoaneurysms) and lesions in different
aortic and anatomic locations (ascending, arch, descending and thoracoabdominal).
Results:The registry enrolled 304patients fromApril 2005 to January 2009.All-causemortality at 30dayswas 7.2%. Freedom
from all cause mortality and freedom from device- and procedure-related mortality at 2 years were 78.5% and 95.9%,
respectively. An average of 1.26 graft components were used per patient, with a technical success of 97.7% irrespective of the
etiology. Early endoleak rate was 4.6%. Perioperatively, stroke and paraplegia were registered in 1.6% and 2.0%, respectively.
Conclusions: The results of RESTORE support the safety of thoracic endovascular aortic repair with the RELAY stent
graft, even in acute and complicated situations. The device was highly efficient in angulated aortic anatomies, with
acceptable mortality and a low rate of neurologic complications. ( J Vasc Surg 2011;53:565-73.)
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tEndovascular repair with stent graft placement is be-
coming the first therapeutic option for thoracic aorta pa-
thologies, both in the elective and in the emergency setting.
Several circumstances can explain why conventional open
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doi:10.1016/j.jvs.2010.09.050epair is progressively being left behind, including the high
erioperative mortality, the need of a highly experienced
ultidisciplinary team, and its elevated rate of major life-
hreatening complications. Endovascular techniques have
riven the evolution of the management of thoracic aortic
isease, enabling minimally invasive repair even in high-risk
atients who are unfit for open surgery. This is especially
dvantageous in the increasingly treated group of patholo-
ies such as those affecting the thoracic aorta.1-8
At present, different endovascular devices are being
ested in prospective or retrospective cohort studies.9-13
esults from previous studies with RELAY (Bolton Medical,
arcelona, Spain) and other devices illustrate a trend toward
ver-improving results as practitioners gain experience with
his technique.14 Comparisons of endovascular and conven-
ional surgical techniques in the treatment of thoracic aortic
neurysms (TAA) and thoracic aortic dissections have shown a
eneficial effect in reductions of acute mortality.10,15,16
Bolton Medical (Barcelona, Spain, and Sunrise, Fla) has
eveloped a device, the RELAY thoracic stent graft system,
hat is intended for the treatment of thoracic aortic diseases.
everal key characteristics in the RELAY stent graft and deliv-
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March 2011566 Riambau et alery system design may confer a certain benefit over existing
devices. RELAY first received European Union approval in
April 2005, and since then,3000 patients have been treated
with RELAY worldwide. In the United States, a phase II
clinical trial has been completed and is awaiting follow-up to
obtain U.S. Food and Drug Administration (FDA) approval.
Much literature concerning endovascular techniques is
related to experiences of single-center and limited case
series.17-21 It appears that collection of multicenter registry
data offers a good opportunity for the evaluation of the
effectiveness of these techniques, because large numbers of
patients can be collected in relatively short periods of time.
Randomized clinical trials have been ruled out because of
several ethical concerns. The RELAY Endovascular Registry
for Thoracic Disease (RESTORE) is a prospective European
registry aimed at evaluating technical and clinical outcomes.
Fig 1. Bare RELAY stent graft configuration.
Fig 2. Configuration of the nonbare RELAY stent (RELAY-NBS).The results in the first 150 patients showed that RELAY was Rfficacious and safe.12 In this article we report complete oper-
tive data and preliminary 2-year follow-up of 304 patients
ho underwent endovascular repair with RELAY.
ETHODS
Device description. The RELAY stent graft is com-
osed of self-expanding nitinol sinusoidal stents sutured to a
olyester vascular graft. A curved nitinol wire, sutured along
he length of the graft fabric, provides longitudinal support.
his design gives moderate column strength to the stent graft
nd also provides flexibility and torque response.
Two different proximal standard configurations—
ELAY, with the proximal bare stent and a nonbare stent
ig 3. A, RELAY during deployment: the apex release mecha-
ism is still closed. B, Apex release mechanism for RELAY and the
on-bare stent RELAY configuration (RELAY-NBS).ELAY (RELAY-NBS) without the proximal bare stent—
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Volume 53, Number 3 Riambau et al 567and one distal configuration are available for RELAY (Figs
1 and 2). The RELAY-NBS configuration is offered for
operators who prefer this proximal end design when treat-
ing pathologies such as acute dissections. The use of one or
the other is according to the operator’s preference.
The delivery system is a four-stage device consisting of
a series of coaxially arranged sheaths and catheters together
with a handle and apex release mechanism (Fig 3). The
hydrophilic outer sheath has an outer diameter of 22F to
26F. More technical details and features of the product
have been described in a previous publication.12
RELAY is available in diameters of 22 to 46 mm.
RELAY offers the longest stent graft in themarket, up to 25
cm in length. In case of specific nonstandard stent graft
design requirement, Bolton Medical offers a customized
product program.
Study design. RESTORE is a multicenter, prospec-
tive, clinical registry that involved 22 centers in seven
European countries (Austria, France, Germany, Greece,
Italy, The Netherlands, and Spain) and aimed at inclusion
of 300 patients. Patient recruitment started in April 2005
and was closed in January 2009. Preliminary results with
the first 150 patients were published in 2008.12
Patient selection and assessment. An initial clinical
evaluation by the physician was needed to determine if a
patient should be considered for treatment with a stent
graft. Suitability for stent graft repair was determined by
medical history, physical examination, and diagnostic im-
aging. Evaluation of a computed tomography (CT) image
of the chest, abdomen, and pelvis was recommended, al-
though other imaging modalities were considered.
All patients who received RELAY for the following
thoracic aortic pathologies were consecutively included:
aneurysm, pseudoaneurysm, penetrating aortic ulcers, in-
tramural hematoma, dissections, and trauma. Those pa-
tients unfit for endovascular repair or who had lesions that
were inappropriate for stent graft placement were excluded.
Regular follow-up examinations were conducted at
intervals as closely as possible to 1, 6, 12, and 24 months to
assess physical condition, lesion diameters and the device,
endoleak, device placement by spiral CT with contrast or
chest radiographs, and adverse events.
Study outcomes. Primary outcome was survival at 2
years. Secondary outcomes included procedural and hospi-
tal outcomes. Technical success rate was defined as the
successful introduction and deployment of the device in the
absence of surgical conversion or death, type I or III
endoleaks, or unwanted graft limb obstruction in the first
24-hour postoperative period. Secondary procedures were
defined as operations or endovascular interventions per-
formed after endograft repair. Adjunctive procedures were
any other procedure that was designed to augment the
effects of the principal procedure. Deployment-related and
systemic complications were also recorded. We followed
the updated Standardized Reporting Practices in Vascular
Surgery of the Society for Vascular Surgery and Interna-
tional Society for Cardiovascular Surgery.22 REthical conduct of the study. All patients signed
nformed consent for their thoracic endovascular aortic
epair procedure and collection of their data.
Statistical analysis. Data were managed and analyzed
ith SAS 9.1.3 software (SAS Institute, Cary, NC). De-
criptive statistics were used to summarize patient out-
omes: counts, mean, standard deviation, minimum, me-
ian, and maximum values were calculated for continuous
ariables, and counts and percentages for categoric vari-
bles. For single proportions, the Wilson recommended
ethod for computing confidence intervals was used. For
ontinuous variables, confidence limits for medians were
ased on a distribution-free method. With respect to sur-
ival rates, nonparametric estimates of the survivor function
t 1 and 2 years were computed by means of the product-
imit method (Kaplan-Meier method), and 95% confidence
ntervals were reported.
RESTORE was submitted to a quality control procedure
y an external company (Trial Form Support Co, Barcelona,
pain) using a random sample of 61 patients representing 20%
f the series to ensure the authenticity of the data transferred
rom the clinical files to the case data forms.
ESULTS
Demographic and clinical features. The study con-
isted of 304 consecutive patients (80.6% men) who were
n average age of 64 years. Demographic features, risk
actors, comorbidities, and history of thoracic surgery are
escribed in Table I.
Several aortic pathologies were approached with
able I. Demographic and clinical characteristics at
nclusion (N  304)
ariable No. (%) or mean (range)
emographics
Male 245 (80.6)
Age, year 64.3 (18-88)
omorbidities
Previous myocardial infarction 37 (12.2)
Previous angor pectoris 33 (10.9)
Congestive heart failure 18 (5.9)
Previous PTCA 37 (12.2)
Previous CABG 14 (4.6)
COPD 90 (29.6)
ardiovascular risk factors
Diabetes 36 (11.8)
Smoking 134 (44.1)
Hypertension 221 (72.3)
Hyperlipidemia 96 (31.6)
Previous carotid disease 30 (9.9)
Renal insufficiency 56 (19.6)
istory of thoracic surgery
Previous thoracotomy 47 (154)
Previous TA procedure 15 (4.9)
Unfit for open TA procedure 132 (43.4)
ABG,Coronary artery bypass grafting;COPD, chronic obstructive pulmo-
ary disease; PTCA, percutaneous transluminal coronary angioplasty; TA,
horacoabdominal.ELAY: TAA was the most frequent (52.9%), followed by
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March 2011568 Riambau et althoracic aortic dissections (29.9%) and traumatic lesions
(13.2%; Table II). The rate of acute aortic pathologies was
high (33.6%). According to the American Society of Anes-
thesiologists (ASA) risk profile classification, 210 patients
(68.9%) scored 3 (Table III).
Procedural and hospital outcomes. General anes-
thesia was used in 284 patients (93.4%), and 20 (6.6%)
Table II. Type of thoracic aorta pathologies approached
with the RELAY endograft system (N  304)
Variable No. %
Atherosclerotic aneurysm 161 53.9
Chronic 146 48.0
Acute (ruptured) 15 4.9
Aortic dissection 91 29.9
Chronic 40 13.2
Subacute 21 6.9
Acute 30 9.8
Degenerative 44 14.4
Chronic 22 7.2
Subacute 11 3.6
Acute 11 3.6
Penetrating ulcer 27 8.9
Chronic 11 3.6
Subacute 9 3.0
Acute 7 2.3
Intramural hematoma 9 3.0
Chronic 2 0.7
Subacute 1 0.3
Acute 6 2.0
Marfan syndrome 1 0.3
Chronic 0 ...
Subacute 0 ...
Acute 1 0.3
Other 10 3.2
Chronic 5 1.6
Subacute 0 ...
Acute 5 1.6
Traumatic lesion 40 13.2
Delayed treatment 16 5.3
Acute treatment 24 7.9
False anastomotic 8 2.6
Chronic 6 2.0
Subacute 1 0.3
Acute 1 0.3
Infection complications 4 1.3
Chronic 1 0.3
Acute 3 1.0
Total 304 100
Table III. American Society of Anesthesiologists (ASA)
risk profile
ASA class (N  301)a No. %
1 24 8.0
2 67 22.2
3 151 50.2
4 51 16.9
5 8 2.7
Average ASA score 2.81
aNot reported in three cases.received local/regional anesthesia. Hypotension was in- duced in 133 patients (43.7%), pharmacologically in 129
42.4%) and by means of rapid heart pacing in 4 (1.3%).
emoral access was the most frequent (82.5%), followed by
liac (9.9%), surgical conduit (4.8%), and aortic (2.8%). The
urgical procedure lasted for an average of 2 hours (range,
.42-9.0 hours). A mean of 1.26 stents per patient was
sed; 1 device was implanted in 237 patients (80%), 2 in 56
18.4%), and 3 in 11 (3.6%). The average covered length
ith RELAY was 163.8 mm. Proximal landing zones were
emarkably in the aortic arch in 240 patients (80%; Fig 4),
eing 134 (44%) in zones Z0 to Z2. If Z0 and Z1 are
onsidered, previous rerouting surgical procedures of up-
er trunks were practiced in 15 patients (25%), upper trunk
ypass in 8 (13.3%), and left subclavian to common carotid
rtery transposition in 4 (6.7%).
A ballooning maneuver was applied in 51 patients
16.8%) to ensure fixation in 30, to treat endoleak in 14,
nd for other reasons in 7 patients. Cerebrospinal drainage
as used in seven patients (3.2%), of which five were
reventive (preoperative) and two were performed during
he thoracic endovascular aneurysm repair procedure.
Overall technical success rate was (97.7%) irrespective of
he etiology, including atherosclerotic aneurysm (98.8%), dis-
ection (95.6%), traumatic lesion (100%), anastomotic an-
urysm (87.5%), and infection complication (100%).
eployment-related complications, implant-related com-
lications, and systemic complications are summarized in
able IV. No procedure had to be abandoned or converted
o an open repair. Stent- or device-related complications
ccurred in only 6.6% of patients. Neurologic complica-
ions occurred in 18 (5.9%) patients, including paraplegia
n 6 (2%), paraparesis in 7 (2.3%), stroke in 4 (1.6%), and
troke and paraplegia in 1 patient. Other systemic compli-
ations were categorized as pulmonary in 40 (13.2%),
ardiac in 14 (4.6%), and renal in 15 (4.9%).
Most patients (95.4%) were free from endoleaks. Pri-
ary type I endoleak occurred in 12 patients (10 endoleaks
ype Ia and 1 type Ib), 2 had type II, and 1 patient had both
ype Ib and type II endoleaks.
Overall, 19 patients died for a 30-daymortality of 7.2%.
he most frequent cause of early death was multiple organ
ailure (21.6%), followed by cardiac arrest (18.9%) and
ortic side branch occlusion (13.5%). Six of 19 deaths were
lassified as device-related or procedure-related.
During the perioperative period, the investigator con-
idered that a significant blood loss occurred in 172 pa-
ients, with a median blood loss of 354 mL (range 20-7000
L). In six patients the blood loss was high, at a mean of
317 mL, and three had additional abdominal or renal
urgical procedures. One presented with a preoperative
ortic rupture, one had a periprocedural aortic rupture after
tent graft placement, and one had right iliac artery bleed-
ng. Blood transfusion (median, 1080 mL; range, 100-
000 mL) was required in 45 patients (26.2%). A total of
03 patients (66.8%) remained under observation in the
ntensive care unit (ICU) for an average of 3.8 days (range,
.0 hours-79 days). The mean patient hospital stay was 18
ays (range, 21-370 days).
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Volume 53, Number 3 Riambau et al 569Follow-up outcomes. Complete follow-up was avail-
able for 196 patients at 1 month, 114 at 12 months, and
50 had follow-up data at 2 years. The average follow-up
for the entire cohort was 334 days. The overall 2-year
survival rate (Fig 5) was high, at 78.5%. Freedom from
procedure- and device-related mortality at the 2-year
follow-up was 95.9% (Fig 6). Three patients abandoned
the registry (1 at the 1-month follow-up evaluation and
2 at the 12-month evaluation). Two conversions to open
surgical procedures were reported (1 at 1 month and 1 at
6 months).
Complications reported during the follow-up con-
Fig 4. Landing zone
Table IV. Perioperative complications (N  304)
Variable No. %
Deployment-stent complications
Failed deployment 4 1.3
Arterial thrombus or emboli 2 0.7
Occlusion of side branches 35 11.5
Rupture of thoracic aorta 1 0.3
Access site bleeding or hematoma 51 16.8
Abandoning the procedure 0 . . .
Conversion to open procedure 0 . . .
Implant-related complications
Inability to advance delivery system 2 0.7
Endograft migration 8 2.6
Endograft obstruction 2 0.7
Other 4 1.3
Systemic complications
Pulmonary 40 13.2
Cardiac 14 4.6
Renal 15 4.9
Cerebral 3 1.0
Neurologic complications
Paraplegia 5 1.6
Recovered paraparesis 7 2.3
Stroke 4 1.3
Stroke and paraplegia 1 0.3
Paraplegia and paraparesis 1 0.3sisted of 1 stent graft migration (type B dissection pre- (enting technical problems during the stent graft place-
ent; no clinical complications associated with the
igration were described during the 24-month follow-
p), 9 procedures (6 transfemoral, 2 transthoracic, and 1
xtra-anatomic), and 40 endoleaks (9 proximal, 10
idgraft, and 21 distal). No retrograde dissections were
eported during this period.
ISCUSSION
This cohort study shows that RELAY is an effective
nd safe stent graft and delivery system for the treatment
f thoracic aortic lesions. RELAY was implanted in 304
atients with acute or chronic thoracic aneurysms and
issections of different causes, such as atherosclerosis,
rauma (mainly arch aortic lesions), or ulcerative, false
nastomotic, infectious, or genetic origin. RELAY was
ffective irrespective of the type of aortic lesion treated,
s indicated by its high technical success of 97.7% and the
levated 2-year survival rate of 78.5%. It is also associated
ith a low rate of systemic complications such as stroke
r paraplegia, endoleaks, and device- or procedure-
elated death.
The results reported here represent the definitive re-
ults of a previously published cohort of the first 150
atients that entered the RESTORE European registry.12
n the present analysis, the sample size is twice as large, and
o our knowledge, is the largest prospective cohort study of
single thoracic endograft ever published. Because of its
arge sample size, outcomes on a diversity of etiologies have
een provided, showing that RELAY is effective in a wide
iversity of aortic disorders.
Compared with the first cohort of patients approached
ith RELAY,12 the patients in the present sample hadmore
evere pathology, as indicated by the higher proportion of
atients who had an acute aortic pathology (33.6% vs
7.6%), there were more patients with aortic dissection
lving the aortic arch.29.9% vs 19.3%), and they had higher surgical risk profile
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March 2011570 Riambau et alaccording to the ASA classification (68.9% scored 3 or
higher in the present analysis vs 62.2%).
The most recent studies of other thoracic endovascular
devices show that a direct comparison of safety and effec-
tiveness between such devices is difficult. Some studies only
included aneurysms of the descending aorta,10,11 the study
design was retrospective,9,13,23 follow-up was 1 year,9,11
and studies reporting patient risk profiles included patients
with considerably fewer surgical risk factors.11,13 One re-
cent retrospective cohort described 180 patients with dif-
ferent thoracic aorta pathologies (aneurysms, dissection,
and ulcers) and gave results of an average follow-up of 5
months.13 The perioperative mortality rate was 7.2% and
increased to 10% at 5 months, a similar trend to that which
was reported in our study. At 5 months, they reported a
27% mortality rate in those patients with aortic aneurysms,
which is higher than our 24.8% mortality rate at 2 years,
although these patients were treated with a dual approach
comprising retrograde visceral artery bypass and endovas-
cular repair. Best survival estimates were reported by Mat-
sumura et al11 in a prospective cohort of patients with
Fig 5. Kaplan-Meier curve shows survival for the REaneurysms of the descending aorta (91.6% survival at 1 wear), but only 41% of patients were considered at high
urgical risk according to the ASA classification. In our
tudy, freedom from device-related mortality at 2 years was
4.3% for aneurysms and 98.7% for dissections.
Despite concerns about endovascular procedures caus-
ng strokes, mainly due to maneuvers in the arch and
cclusion of carotid artery, the incidence of perioperative
trokes in our series was 1.6%, which is notably low com-
ared with other series reporting stroke rates from 2.5% to
.7%.9,11 This difference is especially remarkable, because
he proximal landing zone in RESTORE was in the aortic
rch in 79% (Fig 4), which is much more than in compara-
le studies13,24 or those in which landing in the aortic arch
as excluded.9-11
An endoleak occurred in 4.6% of patients in our
tudy, which is similar to results in other published
tudies.10,11 Interestingly, patients received a mean
umber of 1.26 graft components (22% of patients re-
eived2), which is much less than previous experiences
hat used up to 2.7 graft components per patient.9 This
ccurred because RELAY offers customized grafts with a
endograft system at the 2-year follow-up (n  50).ide range of sizes.
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Volume 53, Number 3 Riambau et al 571Despite this promising overall performance, ICU and
hospital length of stay were considerably high compared
with other reports. Various causes may have negatively
contributed to these results. Patients from the RESTORE
cohort had considerably more severe disease and a high
percentage comprised acute arch aortic lesions, most of
them traumatic and thus with a high surgical risk profile. In
addition, values varied considerably among patients, and
ICU or hospital discharge was delayed in a limited number
of patients due to complications not related to the target
intervention.
This study has several limitations. The observational
design does not allow us to establish causal relationships,
and the lack of control patients hampers direct efficacy and
safety comparisons between devices or even surgery. The
2-year follow-up of 50 patients represents a partial overview
on the final results to be completed and published in the
near future. Although we included a large number of
patients and participating centers, which confers represen-
tativeness to the cohort of patients, there were a consider-
Fig 6. Kaplan-Meier curve shows survival for the RELA
only device-related deaths (n  50).able number of rare or infrequent events. WONCLUSIONS
The present study reports the outcome of a cohort of
atients with thoracic aortic pathologies treated with an inno-
ative endograft system. Technical success and results on
ortality and morbidity with RELAY are at least as good as
hose described in other devices. This study supports the use
f RELAY as a first-line choice for elective and urgent endo-
ascular treatment of thoracic and arch lesions of the aorta.
owever, continuous evolution is needed to overcome the
urrent limitations of thoracic endograft technology.
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